المؤلفون: Fischer L; Department of Medicine III, LMU University Hospital, LMU Munich, Munich, Germany. luca.fischer@med.uni-muenchen.de., Jiang L; Institute for Medical Information Processing, Biometry and Epidemiology, LMU Munich, Munich, Germany., Dürig J; Internal Medicine, St. Josef Hospital, Essen-Werden, Germany., Schmidt C; Department of Medicine III, LMU University Hospital, LMU Munich, Munich, Germany., Stilgenbauer S; Klinik für Innere Medizin III, Ulm University-Medical Center, Ulm, Germany., Bouabdallah K; Department of Hematology and Cellular Therapy, University Hospital of Bordeaux, F-33000, Bordeaux, France., Solal-Celigny P; Institut de Cancérologie de l'Ouest, Saint-Herblain, Bld Jacques Monod, 44805, Saint-Herblain, Cedex, France., Scholz CW; Department of Hematology and Oncology, Vivantes Klinikum Am Urban, Berlin, Germany., Feugier P; Service d'Hématologie et Medecine Interne, Centre Hospitalier Universitaire Nancy-Brabois, Vandoeuvre, France., de Wit M; Klinik für Innere Medizin, Hämatologie, Onkologie und Palliativmedizin, Vivantes Klinikum Neukölln, Berlin, Germany., Trappe RU; Department of Hematology and Oncology, DIAKO Ev. Diakonie-Krankenhaus, Bremen, Germany., Hallek M; Department I for Internal Medicine and Centre of Integrated Oncology Aachen, Bonn, Cologne, Duesseldorf, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany., Graeven U; Department for Hematology, Oncology and Gastroenterology, Kliniken Maria-Hilf Mönchengladbach, Mönchengladbach, Germany., Hänel M; Department of Internal Medicine III, Klinikum Chemnitz, Chemnitz, Germany., Hoffmann M; Medizinische Klinik A, Klinikum der Stadt Ludwigshafen gGmbH, Ludwigshafen, Germany., Delwail V; CHU Poitiers, Poitiers, France., Macro M; Hematology Department, University Hospital, Caen, France., Greiner J; Department. of Internal Medicine, Diakonie-Hospital Stuttgart, 70176, Stuttgart, Germany., Giagounidis AAN; Marien Hospital Düsseldorf, Düsseldorf, 40479, Germany., Dargel B; Medical Center Harz GmbH, Wernigerode, Germany., Durot E; CHU Reims, Hématologie Clinique, F-51100, Reims, France., Foussard C; Department of Pathology, Centre Hospitalier, 49100, Angers, France., Silkenstedt E; Department of Medicine III, LMU University Hospital, LMU Munich, Munich, Germany., Weigert O; Department of Medicine III, LMU University Hospital, LMU Munich, Munich, Germany., Pott C; Department of Internal Medicine II: Hematology and Oncology, University Medical Center Schleswig-Holstein, Campus Kiel, Kiel, Germany., Klapper W; Hematopathology Section, Christian-Albrechts University, Kiel, Germany., Hiddemann W; Department of Medicine III, LMU University Hospital, LMU Munich, Munich, Germany., Unterhalt M; Department of Medicine III, LMU University Hospital, LMU Munich, Munich, Germany., Hoster E; Department of Medicine III, LMU University Hospital, LMU Munich, Munich, Germany.; Institute for Medical Information Processing, Biometry and Epidemiology, LMU Munich, Munich, Germany., Ribrag V; Gustave Roussy, Université Paris-Saclay, DITEP, INSERM U1170, Villejuif, France., Dreyling M; Department of Medicine III, LMU University Hospital, LMU Munich, Munich, Germany.

المصدر: Leukemia [Leukemia] 2024 Jun; Vol. 38 (6), pp. 1307-1314. Date of Electronic Publication: 2024 Apr 27.

نوع المنشور: Journal Article; Clinical Trial, Phase III; Randomized Controlled Trial; Multicenter Study

بيانات الدورية: Publisher: Nature Publishing Group, Specialist Journals Country of Publication: England NLM ID: 8704895 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1476-5551 (Electronic) Linking ISSN: 08876924 NLM ISO Abbreviation: Leukemia Subsets: MEDLINE

مواضيع طبية MeSH: Bortezomib*/administration & dosage , Bortezomib*/therapeutic use , Lymphoma, Mantle-Cell*/drug therapy , Lymphoma, Mantle-Cell*/pathology , Lymphoma, Mantle-Cell*/mortality , Antineoplastic Combined Chemotherapy Protocols*/therapeutic use , Antineoplastic Combined Chemotherapy Protocols*/adverse effects , Dexamethasone*/administration & dosage , Dexamethasone*/therapeutic use , Dexamethasone*/adverse effects , Cytarabine*/administration & dosage , Cytarabine*/therapeutic use , Rituximab*/administration & dosage , Rituximab*/therapeutic use , Neoplasm Recurrence, Local*/drug therapy , Neoplasm Recurrence, Local*/pathology, Humans ; Female ; Male ; Aged ; Middle Aged ; Adult ; Drug Resistance, Neoplasm ; Survival Rate ; Aged, 80 and over ; Follow-Up Studies

المؤلفون: Dreyling M; Department of Medicine III, LMU University Hospital, Munich, Germany. Electronic address: Martin.Dreyling@med.uni-muenchen.de., Doorduijn J; Department of Hematology, Erasmus MC Cancer Institute, University Medical Center Rotterdam, Rotterdam, Netherlands., Giné E; Hematology Department, Hospital Clínic de Barcelona, IDIBAPS, Barcelona, Spain., Jerkeman M; Cancer Centre, Lund University Faculty of Medicine, Lund, Sweden., Walewski J; Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland., Hutchings M; Department of Haematology and Phase 1 Unit, Rigshospitalet, Copenhagen, Denmark., Mey U; Oncology and Hematology, Kantonsspital Graubuenden, Chur, Switzerland., Riise J; Department of Oncology, Oslo University Hospital, Oslo, Norway., Trneny M; First Faculty of Medicine, Charles University Hospital, Prague, Czech Republic., Vergote V; Department of Hematology, University Hospitals Leuven, Leuven, Belgium., Shpilberg O; Adelson School of Medicine, Ariel University, Ariel, Israel; Institute of Hematology, Assuta Medical Center, Tel Aviv, Israel., Gomes da Silva M; Department of Hematology, Portuguese Institute of Oncology, Lisbon, Portugal., Leppä S; Comprehensive Cancer Center, University of Helsinki and Helsinki University Hospital, Helsinki, Finland., Jiang L; Institute for Medical Information Processing, Biometry, and Epidemiology (IBE), Faculty of Medicine, LMU Munich, Munich, Germany., Stilgenbauer S; Department of Internal Medicine III, Ulm University Hospital, Ulm, Germany., Kerkhoff A; Medizinische Klinik A, Universitätsklinikum Münster, Münster, Germany., Jachimowicz RD; Department I of Internal Medicine, Center for Integrated Oncology and University Hospital Cologne, University of Cologne, Cologne, Germany., Celli M; Division of Hematology, Infermi Hospital, Rimini, Italy., Hess G; Department of Hematology and Medical Oncology, Medical School of the Johannes Gutenberg-University, Mainz, Germany., Arcaini L; Department of Molecular Medicine, University of Pavia, Pavia, Italy; Division of Hematology, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy., Visco C; Hematology Department, San Bortolo Hospital, Vicenza, Italy; Department of Medicine, University of Verona, Verona, Italy., van Meerten T; Department of Hematology, University Medical Center Groningen, Groningen, Netherlands., Wirths S; Department of Hematology, Oncology, Clinical Immunology and Rheumatology, Center for Internal Medicine, University Hospital Tuebingen, Tübingen, Germany., Zinzani PL; Istituto di Ematologia 'Seràgnoli', IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy; Dipartimento di Scienze Mediche e Chirurgiche, Università di Bologna, Bologna, Italy., Novak U; Department of Medical Oncology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland., Herhaus P; Department of Internal Medicine III, Technical University Munich, Germany TU Munich, Munich, Germany., Benedetti F; Hematology and Stem Cell Transplantation, Azienda Ospedaliera Universitaria di Verona, Verona, Italy., Sonnevi K; Department of Medicine Huddinge, Karolinska Institutet, Stockholm, Sweden., Hanoun C; Department of Hematology and Stem Cell Transplantation, University Hospital Essen, Essen, Germany., Hänel M; Department of Internal Medicine III, Klinikum Chemnitz, Chemnitz, Germany., Dierlamm J; Department of Internal Medicine II, UKE Hamburg, Hamburg, Germany., Pott C; Department of Medicine II, University Hospital Schleswig-Holstein - Campus Kiel, Kiel, Germany., Klapper W; Department of Pathology, Hematopathology Section and Lymph Node Registry, University Hospital Schleswig-Holstein - Campus Kiel, Kiel, Germany., Gözel D; Department of Medicine III, LMU University Hospital, Munich, Germany., Schmidt C; Department of Medicine III, LMU University Hospital, Munich, Germany., Unterhalt M; Department of Medicine III, LMU University Hospital, Munich, Germany., Ladetto M; Department of Translational Medicine, Division of Hematology, University of Eastern Piedmont and SCDU Ematologia, Azienda Ospedaliera Santi Antonio e Biagio e Cesare Arrigo, Alessandria, Italy., Hoster E; Institute for Medical Information Processing, Biometry, and Epidemiology (IBE), Faculty of Medicine, LMU Munich, Munich, Germany.

المصدر: Lancet (London, England) [Lancet] 2024 May 25; Vol. 403 (10441), pp. 2293-2306. Date of Electronic Publication: 2024 May 02.

نوع المنشور: Journal Article; Randomized Controlled Trial; Clinical Trial, Phase III; Multicenter Study

بيانات الدورية: Publisher: Elsevier Country of Publication: England NLM ID: 2985213R Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1474-547X (Electronic) Linking ISSN: 01406736 NLM ISO Abbreviation: Lancet Subsets: MEDLINE

مواضيع طبية MeSH: Lymphoma, Mantle-Cell*/therapy , Lymphoma, Mantle-Cell*/drug therapy , Adenine*/analogs & derivatives , Adenine*/administration & dosage , Adenine*/therapeutic use , Piperidines*/administration & dosage , Piperidines*/therapeutic use , Antineoplastic Combined Chemotherapy Protocols*/therapeutic use , Transplantation, Autologous* , Vincristine*/administration & dosage , Vincristine*/therapeutic use , Rituximab*/administration & dosage , Rituximab*/therapeutic use , Cyclophosphamide*/administration & dosage , Cyclophosphamide*/therapeutic use, Humans ; Middle Aged ; Male ; Female ; Adult ; Aged ; Europe ; Hematopoietic Stem Cell Transplantation/methods ; Prednisone/administration & dosage ; Prednisone/therapeutic use ; Doxorubicin/administration & dosage ; Young Adult ; Dexamethasone/administration & dosage ; Dexamethasone/therapeutic use ; Adolescent ; Israel ; Treatment Outcome

المؤلفون: Hoster E; Institute for Medical Informatics, Biometry, and Epidemiology (IBE), LMU Munich, Munich, Germany.; Department of Internal Medicine III, University Hospital LMU Munich, Munich, Germany., Delfau-Larue MH; Department of Immunobiology and Inserm U955, Université Hôpital Henri Mondor, Créteil, France., Macintyre E; Laboratory of Onco-Hematology, Université Paris Cité, Institut Necker-Enfants Malades and Assistance Publique-Hôpitaux de Paris, Paris, France., Jiang L; Institute for Medical Informatics, Biometry, and Epidemiology (IBE), LMU Munich, Munich, Germany., Stilgenbauer S; Department of Internal Medicine III, University of Ulm, Ulm, Germany., Vehling-Kaiser U; VK&K Studien GbR, Landshut, Germany., Salles G; Hospices Civils de Lyon, Université Claude Bernard, Centre Hospitalier Lyon-Sud, Pierre Bénite, France.; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY., Thieblemont C; Department of Hematology, Hôpital Saint Louis, Paris, France., Tilly H; Department of Hematology and U1245, Centre Henri Becquerel, Rouen, France., Wirths S; Department of Medicine II, University of Tübingen, Tübingen, Germany., Feugier P; Department of Hematology and INSERM 1256, University of Lorraine, Vandoeuvre les Nancy, France., Hübel K; Klinik I für Innere Medizin, Universität zu Köln, Köln, Germany., Schmidt C; Department of Internal Medicine III, University Hospital LMU Munich, Munich, Germany., Ribrag V; Institut Gustave Roussy, Villejuif, France., Kluin-Nelemans JC; Department of Hematology, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands., Dreyling M; Department of Internal Medicine III, University Hospital LMU Munich, Munich, Germany., Pott C; Department of Medicine, University Hospital Schleswig-Holstein Campus Kiel/Christian-Albrechts University Kiel, Germany.

مؤلفون مشاركون: European MCL MRD Working Group and the European MCL Network

المصدر: Journal of clinical oncology : official journal of the American Society of Clinical Oncology [J Clin Oncol] 2024 Feb 10; Vol. 42 (5), pp. 538-549. Date of Electronic Publication: 2023 Nov 22.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: American Society of Clinical Oncology Country of Publication: United States NLM ID: 8309333 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1527-7755 (Electronic) Linking ISSN: 0732183X NLM ISO Abbreviation: J Clin Oncol Subsets: MEDLINE

مواضيع طبية MeSH: Lymphoma, Mantle-Cell*/therapy, Aged ; Humans ; Middle Aged ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Cyclophosphamide/therapeutic use ; Doxorubicin/therapeutic use ; Multicenter Studies as Topic ; Neoplasm, Residual/drug therapy ; Prednisone/therapeutic use ; Randomized Controlled Trials as Topic ; Rituximab/therapeutic use ; Vincristine/therapeutic use

المؤلفون: Fischer L; Department of Medicine III, University Hospital, LMU Munich, Munich, Germany. luca.fischer@med.uni-muenchen.de., Jiang L; Institute for Medical Information Processing, Biometry and Epidemiology, LMU Munich, Munich, Germany., Bittenbring JT; University of Saarland, University Hospital, Homburg (Saar), Homburg, Germany., Huebel K; University of Cologne, Cologne, Germany., Schmidt C; Department of Medicine III, University Hospital, LMU Munich, Munich, Germany., Duell J; Department of Internal Medicine II, University Hospital Würzburg, University of Würzburg, Würzburg, Germany., Metzner B; University Clinic for Oncology and Hematology, Klinikum Oldenburg, Oldenburg, Germany., Krauter J; Department of Internal Medicine III, Braunschweig Municipal Hospital, Brunswick, Germany., Glass B; Department of Hematology, HELIOS Klinikum Berlin-Buch, Berlin, Germany., Huettmann A; Department of Hematology and Stem Cell Transplantation, West German Cancer Center Essen, University Hospital Essen (AöR), University of Duisburg-Essen, Essen, Germany., Schaefer-Eckart K; Medical Clinic V, Hematology and Oncology, Klinikum Nuernberg, Nuernberg, Germany., Silkenstedt E; Department of Medicine III, University Hospital, LMU Munich, Munich, Germany., Klapper W; Department of Pathology, Hematopathology Section, University Hospital Schleswig-Holstein, Christian-Albrecht-University of Kiel, Kiel, Germany., Hiddemann W; Department of Medicine III, University Hospital, LMU Munich, Munich, Germany., Unterhalt M; Department of Medicine III, University Hospital, LMU Munich, Munich, Germany., Dreyling M; Department of Medicine III, University Hospital, LMU Munich, Munich, Germany., Hoster E; Department of Medicine III, University Hospital, LMU Munich, Munich, Germany.; Institute for Medical Information Processing, Biometry and Epidemiology, LMU Munich, Munich, Germany.

مؤلفون مشاركون: German Lymphoma Alliance (GLA) and the German Low-Grade Lymphoma Study Group (GLSG)

المصدر: Annals of hematology [Ann Hematol] 2023 Oct; Vol. 102 (10), pp. 2791-2801. Date of Electronic Publication: 2023 Aug 08.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: Springer Verlag Country of Publication: Germany NLM ID: 9107334 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1432-0584 (Electronic) Linking ISSN: 09395555 NLM ISO Abbreviation: Ann Hematol Subsets: MEDLINE

مواضيع طبية MeSH: Lymphoma, Mantle-Cell*/drug therapy, Adult ; Humans ; Rituximab ; Prospective Studies ; Antibodies, Monoclonal, Murine-Derived ; Neoplasm Recurrence, Local/drug therapy ; Vincristine ; Cyclophosphamide ; Prednisone ; Doxorubicin ; Antineoplastic Combined Chemotherapy Protocols

المؤلفون: Scheubeck G; Department of Medicine III, LMU University Hospital, Munich, Germany. gabriel.scheubeck@med.uni-muenchen.de., Jiang L; Institute for Medical Information Processing, Biometry, and Epidemiology, LMU Munich, Munich, Germany., Hermine O; University Hospital, Paris, France., Kluin-Nelemans HC; Department of Hematology, University Medical Center Groningen, University of Groningen, Groningen, Netherlands., Schmidt C; Department of Medicine III, LMU University Hospital, Munich, Germany., Unterhalt M; Department of Medicine III, LMU University Hospital, Munich, Germany., Rosenwald A; Institute of Pathology, University of Wuerzburg, Wuerzburg, Germany., Klapper W; Department of Pathology, Hematopathology Section, University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany., Evangelista A; Unit of Clinical Epidemiology, Azienda Ospedaliera Universitaria Città della Salute e della Scienza and CPO Piemonte, Turin, Italy., Ladetto M; Hematology, Azienda Ospedaliera SS Antonio e Biagio e Cesare Arrigo, Alessandria, Italy., Jerkeman M; Skane University Hospital, Lund, Sweden., Ferrero S; Division of Hematology, Department of Molecular Biotechnologies and Health Sciences University of Torino/AOU 'Città della Salute e della Scienza di Torino', Turin, Italy., Dreyling M; Department of Medicine III, LMU University Hospital, Munich, Germany., Hoster E; Department of Medicine III, LMU University Hospital, Munich, Germany.; Institute for Medical Information Processing, Biometry, and Epidemiology, LMU Munich, Munich, Germany.

المصدر: Leukemia [Leukemia] 2023 Sep; Vol. 37 (9), pp. 1887-1894. Date of Electronic Publication: 2023 Jul 26.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: Nature Publishing Group, Specialist Journals Country of Publication: England NLM ID: 8704895 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1476-5551 (Electronic) Linking ISSN: 08876924 NLM ISO Abbreviation: Leukemia Subsets: MEDLINE

مواضيع طبية MeSH: Lymphoma, Mantle-Cell*/drug therapy, Adult ; Humans ; Aged ; Ki-67 Antigen ; Tumor Suppressor Protein p53/genetics ; Prospective Studies ; Prognosis

المؤلفون: Hermine O; Department Hematology, Hôpital Necker, Assistance Publique Hôpitaux de Paris, University Paris Descartes, Paris, France.; INSERM U1163 and CNRS 8254, Imagine Institute, Université Sorbonne Paris Cité, Paris, France., Jiang L; Institute of Medical Informatics, Biometry, and Epidemiology, University of Munich, Munich, Germany., Walewski J; Department of Lymphoid Malignancies, The Maria Skłodowska-Curie Memorial Institute and Oncology Center, Warsaw, Poland., Bosly A; CHU UCL Mont-Godinne-Dinant, Yvoir, Belgium., Thieblemont C; Assistance Publique-Hôpitaux de Paris, Hemato-Oncologie, Hôpital Saint Louis, University of Paris, Paris, France., Szymczyk M; Department of Lymphoid Malignancies, The Maria Skłodowska-Curie Memorial Institute and Oncology Center, Warsaw, Poland., Pott C; Second Medical Department, University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany., Salles G; Hospices Civils de Lyon, Université Claude Bernard, Centre Hospitalier Lyon-Sud, Pierre Bénite, France.; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY., Feugier P; Service d'Hematologie, Vandoevre les Nancy, France., Hübel K; Klinik I für Innere Medizin, Universität zu Köln, Köln, Germany., Haioun C; Lymphoid Malignancies Unit, Hospital Henri Mondor, Créteil, France., Casasnovas RO; Hématologie Clinique, Hôpital Le Bocage-CHU Dijon, Dijon, France., Schmidt C; Department of Internal Medicine III, University Hospital Munich, Munich, Germany., Bouabdallah K; CHU Bordeaux, Service d'hématologie, Bordeaux, France., Ribrag V; Institut Gustave Roussy, Villejuif, France., Kanz L; Department of Medicine II, University of Tübingen, Tübingen, Germany., Dürig J; Klinik für Hämatologie, Universitätsklinikum Essen, Essen, Germany., Metzner B; Universitätsklinik für Onkologie und Hämatologie, Klinikum Oldenburg, Oldenburg, Germany., Sibon D; Department Hematology, Hôpital Necker, Assistance Publique Hôpitaux de Paris, University Paris Descartes, Paris, France., Cheminant M; Department Hematology, Hôpital Necker, Assistance Publique Hôpitaux de Paris, University Paris Descartes, Paris, France., Burroni B; Pathology Department, Cochin University Hospital, AP-HP, Paris, France., Klapper W; Department of Pathology, Hematopathology Section and Lymph Node Registry, University of Kiel, Kiel, Germany., Hiddemann W; Department of Internal Medicine III, University Hospital Munich, Munich, Germany., Unterhalt M; Department of Internal Medicine III, University Hospital Munich, Munich, Germany., Hoster E; Institute of Medical Informatics, Biometry, and Epidemiology, University of Munich, Munich, Germany.; Department of Internal Medicine III, University Hospital Munich, Munich, Germany., Dreyling M; Department of Internal Medicine III, University Hospital Munich, Munich, Germany.

مؤلفون مشاركون: European Mantle Cell Lymphoma Network

المصدر: Journal of clinical oncology : official journal of the American Society of Clinical Oncology [J Clin Oncol] 2023 Jan 20; Vol. 41 (3), pp. 479-484. Date of Electronic Publication: 2022 Dec 05.

نوع المنشور: Randomized Controlled Trial; Journal Article; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: American Society of Clinical Oncology Country of Publication: United States NLM ID: 8309333 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1527-7755 (Electronic) Linking ISSN: 0732183X NLM ISO Abbreviation: J Clin Oncol Subsets: MEDLINE

مواضيع طبية MeSH: Lymphoma, Mantle-Cell*/drug therapy , Lymphoma, Mantle-Cell*/pathology , Hematopoietic Stem Cell Transplantation*/methods, Adult ; Humans ; Aged ; Rituximab ; Follow-Up Studies ; Cytarabine ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Cyclophosphamide ; Prednisone ; Doxorubicin ; Vincristine